{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:06:59Z","timestamp":1790842019190,"version":"4.1.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 and KO-539, in relapsed and refractory (R\/R) acute myeloid leukemia (AML) with KMT2A rearrangement or mutant NPM1, with overall response rates (ORR) of 53% (32\/60) and 40% (8\/20), respectively. The addition of the novel drug pivekimab sunirine, a first-in-class antibody\u2013drug conjugate targeting CD123, to azacitidine and venetoclax in R\/R AML resulted in an ORR of 45% (41\/91), which rose to 53% in those who were venetoclax na\u00efve. Additional novel triplet treatment combinations included the addition of magrolimab, an anti-CD47 antibody, to azacitidine and venetoclax, with an ORR of 81% (35\/43) in newly diagnosed AML, including an ORR of 74% (20\/27) in TP53 mutated AML. The addition of the FLT3 inhibitor gilteritinib to azacitidine\/venetoclax was also featured, with an ORR of 100% (27\/27) in newly diagnosed AML and an ORR of 70% (14\/20) in R\/R AML.<\/jats:p>","DOI":"10.1186\/s13045-023-01411-x","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:03:59Z","timestamp":1677834239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting"],"prefix":"10.1186","volume":"16","author":[{"given":"Katherine W.","family":"DiNardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"3","key":"1411_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254\u201366. https:\/\/doi.org\/10.1056\/NEJMoa041974.","journal-title":"N Engl J Med"},{"issue":"4","key":"1411_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2141.2006.06301.x","volume":"135","author":"J Basecke","year":"2006","unstructured":"Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol. 2006;135(4):438\u201349. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06301.x.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"1411_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2022-164849","volume":"140","author":"GC Issa","year":"2022","unstructured":"Issa GC, Aldoss I, DiPersio JF, Cuglievan B, Stone RM, Arellano ML, et al. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study. Blood. 2022;140(Supplement 1):150\u20132. https:\/\/doi.org\/10.1182\/blood-2022-164849.","journal-title":"Blood"},{"key":"1411_CR4","doi-asserted-by":"crossref","unstructured":"Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, et al. Update on a Phase 1\/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Oral session presented at: 64th Annual Meeting of the American Society of Hematology; 2022 Dec 10\u201313; New Orleans.","DOI":"10.1182\/blood-2022-167412"},{"key":"1411_CR5","doi-asserted-by":"crossref","unstructured":"Daver N, Montesinos P, Aribi A, Marconi G, Altman JK, Wang ES, et al. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML). Oral session presented at: 64th Annual Meeting of the American Society of Hematology; 2022 Dec 10\u201313; New Orleans.","DOI":"10.1182\/blood-2022-158030"},{"key":"1411_CR6","doi-asserted-by":"crossref","unstructured":"Daver N, Senapati J, Maiti A, Loghavi S, Kadia TM, DiNardo CD, et al. Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML. Oral session presented at: 64th Annual Meeting of the American Society of Hematology; 2022 Dec 10\u201313; New Orleans.","DOI":"10.1182\/blood-2022-170188"},{"key":"1411_CR7","doi-asserted-by":"crossref","unstructured":"Short N, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, et al. Updated Results from a Phase I\/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia. Oral session presented at: 64th Annual Meeting of the American Society of Hematology; 2022 Dec 10\u201313; New Orleans.","DOI":"10.1182\/blood-2022-157210"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01411-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:06:59Z","timestamp":1677834419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01411-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01411-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"12 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Thomas W. LeBlanc is currently, or has recently been a consultant for AbbVie, Agios\/Servier, Astellas, AstraZeneca, BlueNote, BMS\/Celgene, CareVive, Flatiron, Genentech, GSK, Novartis, and Pfizer. He has served on recent advisory boards for AbbVie, Agios, and BMS. He has received honoraria from AbbVie, Agios, Astellas, BMS\/Celgene, and Incyte for recent speaking engagements. He has also received recent research funding from the American Cancer Society, AstraZeneca, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the National Institute of Nursing Research\/ National Institutes of Health, and Seattle Genetics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}